Skip to main
KIDS

OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics (KIDS) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

OrthoPediatrics Corp has demonstrated a solid financial performance, reflected in a 50 basis points year-over-year increase in gross margin and a significant 280 basis points improvement in adjusted EBITDA margin. The company reported a 17.3% growth in Trauma & Deformity sales, surpassing expectations, alongside positive management indications of over 20% growth in OPSB during the third quarter, contributing to a strong outlook. Additionally, consistent revenue growth expectations of over 12% in the coming years, combined with anticipated operating leverage from new product introductions, position the company favorably for continued financial expansion.

Bears say

OrthoPediatrics Corp faces a challenging financial outlook due to several key factors, including a slowdown in revenue growth, with a decline from 15.7% in Q2 2025 to 12.2% in Q3 2025, indicating potential issues with sales and market demand. The company has also lowered its full-year guidance for 2025 to $233.5M-$234.5M, highlighting concerns over disappointing sales from newly acquired products and an overall decline in deployment of sales sets, decreasing from $17.2M TTM to $16.0M TTM. Furthermore, the risks associated with slower organic growth and productivity declines among distributors suggest that margin improvements and cash flow remain uncertain, raising further alarms regarding the company's financial health.

OrthoPediatrics (KIDS) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OrthoPediatrics (KIDS) Forecast

Analysts have given OrthoPediatrics (KIDS) a Strong Buy based on their latest research and market trends.

According to 9 analysts, OrthoPediatrics (KIDS) has a Strong Buy consensus rating as of Apr 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OrthoPediatrics (KIDS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.